Regeneron stock just slipped on a banana peel, hitting a 52-week low at $493.15 before closing at $496.06. Despite this dip, ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Apple Inc.'s stock has struggled to find positive momentum this year, and analysts at Needham & Company don't see major catalysts ahead that can help put shares on a better course.

Regeneron Pharmaceuticals saw a downgrade from Wells Fargo, slicing its stock rating from "overweight" to "equal weight" and ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094.

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

Adam Turnquist, a technical strategist at LPL Financial, said the recovery in stock-market breadth is a particularly convincing bullish "tell" suggesting that the market's recovery appears to be on ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

23andMe has said it wants to allow new bids by both parties with a deadline of 12th June, according to a Financial Times ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities.